Einstein Doubles Customer Base after Launching Mobile Apps
Einstein Exchange, one of the world’s fastest growing cryptocurrency exchange announced extraordinary customer growth as a result of the launch of the Company’s free mobile wallet & trading applications. Within 14 days of launch, the Einstein added over 60,000 new customers, representing over 100% growth in total customer count, and over 20,000 verifying their identity within the app’s proprietary KYC engine.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190402005150/en/
Einstein Exchange's new cryptocurrency mobile wallet, designed for simplicity and ease of use, available in 12 different languages. (Photo: Business Wire)
Einstein released its cryptocurrency mobile applications on Apple’s iOS Store & Google’s Play Store in the first week of March 2019 featuring free cryptocurrency trading, in-app identity verification, unlimited Visa (NYSE: V) & Mastercard (NYSE: MA) funding with mobile 3DS security and unlimited $10 referral bonus to all customers who verify their identities.
Both Apple (NASDAQ: APPL) & Google’s (NASDAQ: GOOG) Android apps soared to the Top New Free and Top 100 Free Finance apps, respectively, attracting over 10,000 new downloads per day and driving over 19,000% increase in the exchange’s trade volume.
“Einstein’s mobile applications had a stunning & extraordinary debut. It took us 18 months to acquire our first 65,000 customers, whereas our mobile apps clearly showed tremendous value on a global scale for us to be fortunate to acquire over 60,000 new customers within 2 weeks,” said Michael Gokturk, Einstein’s CEO.
“We still have much to do to attract new customers and grow the overall market size, but this type of adoption gives us the optimism and market validation we need to continue innovating and pushing the industry forward.”
Einstein Convert, the Company’s featured mobile crypto wallets, enable customers to Convert, Earn & Spend over 19 different types of cryptocurrency from the safety and security of their mobile phones. Customers can convert into any cryptocurrency commission-free, earn $10 for every friend they refer to the app, and spend all or part of their wallet balance by using their free Einstein electronic credit-card issued right to their mobile phone.
“The apps are simple and beautifully designed,” added Gokturk, “but the feature that exceeded our wildest expectations was our referral program. We didn’t promote or market the app with traditional ads, our customers loved the app so much they became our biggest acquisition channel and we couldn’t be happier.”
About Einstein Exchange
Einstein Exchange is a Canada-based crypto-currency exchange launched in 2017 which now enables over 125,000 customers to convert, earn and spend crypto-currencies such as Bitcoin, Ethereum, Litecoin and more, all for free. Einstein is registered with FINTRAC in Canada as a Virtual Currency Exchange. Einstein works with all major banks and is licensed to accept Visa, MasterCard, Interac, Flexepin, and SKRILL for customers seeking to invest in crypto-currency.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190402005150/en/
Contact information
Michael Gokturk
Telephone: +1-877-787-6885
Email:
press@einstein.exchange
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 23:32:00 EEST | Press release
Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management to fully concentrate on on-field performance, ensuring that collective focus remains on
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 21:00:00 EEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10 th Anniversary Year of NAHYCO ® Technology6.6.2025 17:00:00 EEST | Press release
IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603094257/en/ IBSA’s stand at IMCAS Asia 2025 As part of the congress, IBSA Derma will host a scientific symposium titled “The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line” scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 15:00:00 EEST | Press release
HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #H
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom